Literature DB >> 7669818

Impaired saccadic eye movements on stationary targets in patients with schizophrenia spectrum disorder.

M Matsui1, M Kurachi.   

Abstract

This study examined tracking eye movements on predetermined stationary targets in patients with schizophrenia spectrum disorder. The targets were 8 black points or 8 arabic-numbered points placed on the circumference of a circle. Self-paced eye movements during clockwise tracking of these points by 23 patients and 23 normal controls were recorded using an infrared eye-mark recorder. Eye movements were analyzed at two settings: firstly, when "fixation point" was defined as a point at which a gaze was held for at least 200-ms; and secondly, when held for at least 100-ms. The results indicated that at the 200-ms setting schizophrenic patients track with significantly fewer correct scores and more deviant scores than controls under black-point conditions. At the 100-ms setting, however, the correct scores of patients were not significantly different from those of controls, although patients displayed more aberrant paths than controls. The superfluous fixations in the patients improved significantly under numbered-point conditions, but patients still achieved lower correct scores than controls. Four of the 23 patients exhibited centering (aberrant path directed toward the center point), suggesting immature control of eye movements under black-point conditions, but not numbered-point conditions. These results suggest that some schizophrenic patients viewed the targets too quickly, and that they have impaired directed attention, which can be improved by cues, and may have impaired preprogramming of eye movements, which is not improved by external cues.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7669818     DOI: 10.1007/bf02193084

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  14 in total

1.  Scanning eye movements in schizophrenic patients. Relationship to clinical symptoms and regional cerebral blood flow using 123I-IMP SPECT.

Authors:  M Tsunoda; M Kurachi; S Yuasa; Y Kadono; M Matsui; A Shimizu
Journal:  Schizophr Res       Date:  1992-07       Impact factor: 4.939

2.  Eye-tracking performance and engagement of attention.

Authors:  C Shagass; R A Roemer; M Amadeo
Journal:  Arch Gen Psychiatry       Date:  1976-01

3.  Smooth pursuit eye movements, attention, and schizophrenia.

Authors:  P S Holzman; D L Levy; L R Proctor
Journal:  Arch Gen Psychiatry       Date:  1976-12

4.  Impaired performance in a saccadic tracking task in schizophrenic patients.

Authors:  F M Reischies; R D Stieglitz; A Mielewczyk; A Vogel
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

5.  Eye movements during perception of pictures in chronic schizophrenia.

Authors:  H Moriya; K Ando; T Kojima; Y Shimazono; R Ogiwara
Journal:  Folia Psychiatr Neurol Jpn       Date:  1972

6.  Visuomotor performance of schizophrenic patients and normal controls in a picture viewing task.

Authors:  W Gaebel; G Ulrich; K Frick
Journal:  Biol Psychiatry       Date:  1987-10       Impact factor: 13.382

7.  Disturbed smooth pursuit and saccadic eye movements in schizophrenia.

Authors:  W Schmid-Burgk; W Becker; V Diekmann; R Jürgens; H H Kornhuber
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1982

8.  Limited visual search on the WAIS Picture Completion test in patients with schizophrenia.

Authors:  M Kurachi; M Matsui; K Kiba; M Suzuki; M Tsunoda; N Yamaguchi
Journal:  Schizophr Res       Date:  1994-04       Impact factor: 4.939

9.  The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy.

Authors:  P F Liddle
Journal:  Br J Psychiatry       Date:  1987-08       Impact factor: 9.319

View more
  1 in total

1.  Saccadic eye movements and regional cerebral blood flow in schizophrenic patients.

Authors:  M Matsui; M Kurachi; S Yuasa; M Aso; Y Tonoya; S Nohara; O Saitoh
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.